Zila Receives Nasdaq Notice Letter
September 26 2008 - 5:05PM
Business Wire
Zila, Inc. (NASDAQ:ZILAD) today announced that it received a Nasdaq
Staff Determination Letter on September 22, 2008 informing the
company that it is subject to delisting based upon the company's
failure to comply with Marketplace Rules 4450(a)(5) and 4350. In
accordance with Marketplace Rule 4450(e)(2), the company was given
until September 16, 2008 to achieve a closing bid price of the
company�s common stock of $1.00 per share or more for a minimum of
10 consecutive business days. Zila has effectuated a 1 for 7
reverse stock split, which took effect on September 17, 2008. As of
the close of trading today, the closing bid price of the company�s
stock has been above $1.00 per share for eight consecutive days. If
the closing bid price of the company�s common stock is above $1.00
per share for the next two business days, the company will regain
compliance with Marketplace Rule 4450(a)(5). Consistent with
Marketplace Rule 4350(d)(4) the company has until the earlier of
its next annual shareholders� meeting or December 17, 2008 to name
a third director as a member of the Audit Committee so that the
company regains compliance with the requirements of Marketplace
Rule 4350. The company said that it expects to fill the Audit
Committee vacancy within the timeframe required by the Nasdaq
Marketplace Rules. About Zila, Inc. Zila, Inc., is a fully
integrated oral diagnostic company dedicated to the prevention,
detection and treatment of oral cancer and periodontal disease.
ViziLite� Plus, the company's flagship product for the early
detection of oral abnormalities that could lead to cancer, is the
first and only adjunctive medical device cleared by the FDA for use
in a population at increased risk for oral cancer. In addition,
Zila designs, manufactures and markets a suite of proprietary
products sold exclusively and directly to dental professionals for
periodontal disease, including the Rota-dent(R) Professional
Powered Brush, the Pro-Select(R) Platinum ultrasonic scaler and a
portfolio of oral pharmaceutical products for both in-office and
home-care use. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely affect revenue, profitability, cash
flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2007 and Form 10-Q for the quarter ended
April 30, 2008. For more information about the company and its
products, please visit www.zila.com.
Zila (MM) (NASDAQ:ZILAD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Zila (MM) (NASDAQ:ZILAD)
Historical Stock Chart
From Dec 2023 to Dec 2024